Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial
- 1 October 2005
- journal article
- clinical trial
- Published by Elsevier in The Lancet Oncology
- Vol. 6 (10), 757-764
- https://doi.org/10.1016/s1470-2045(05)70292-8
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumorsRadiotherapy and Oncology, 2004
- Hypoxia-Inducible Factor 1α Expression as an Intrinsic Marker of HypoxiaClinical Cancer Research, 2004
- The role of Osteopontin in tumor metastasisJournal of Surgical Research, 2004
- The hypoxic tumor microenvironment and gene expressionSeminars in Radiation Oncology, 2004
- Exploiting tumour hypoxia in cancer treatmentNature Reviews Cancer, 2004
- 475 The prognostic value of serum osteopontin, HIF-1 alpha and pO2 measurements in advanced head and neck tumors treated by radiotherapyEuropean Journal of Cancer Supplements, 2003
- OsteopontinCritical Reviews in Oral Biology & Medicine, 2000
- Modification of hypoxia-induced radioresistance in tumors by the use of oxygen and sensitizersSeminars in Radiation Oncology, 1996
- Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic FactorsJNCI Journal of the National Cancer Institute, 1994
- Measurement of Human Tumour Oxygenation Status by a Polarographic Needle Electrode: An analysis of inter- and intratumour heterogeneityActa Oncologica, 1994